In today’s session Vertex Pharmaceuticals Incorporated (VRTX) registered an unusually high (308) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious VRTX increase. With 308 contracts traded and 5034 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: VRTX161021C00090000 closed last at: $1.25 or 7.4% down. About 590,763 shares traded hands. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has declined 3.51% since March 9, 2016 and is downtrending. It has underperformed by 10.92% the S&P500.
Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on October, 26.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage
Out of 14 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 10 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 71% are positive. $160 is the highest target while $88 is the lowest. The $133.05 average target is 62.49% above today’s ($81.88) stock price. Vertex Pharmaceuticals has been the topic of 27 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The rating was upgraded by Barclays Capital on Monday, September 14 to “Overweight”. The firm has “Buy” rating given on Thursday, February 4 by Argus Research. The stock has “Market Perform” rating given by BMO Capital Markets on Thursday, April 7. Oppenheimer initiated the shares of VRTX in a report on Thursday, February 11 with “Perform” rating. The company was initiated on Friday, February 5 by Leerink Swann. The stock has “Buy” rating given by Argus Research on Monday, September 28. The firm has “Overweight” rating given on Friday, October 2 by Morgan Stanley. The company was initiated on Tuesday, September 13 by Raymond James. Stifel Nicolaus maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, September 15 with “Buy” rating. The company was initiated on Wednesday, September 9 by Jefferies.
According to Zacks Investment Research, “Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)”
Insitutional Activity: The institutional sentiment increased to 1.14 in Q2 2016. Its up 0.18, from 0.96 in 2016Q1. The ratio improved, as 53 funds sold all Vertex Pharmaceuticals Incorporated shares owned while 139 reduced positions. 43 funds bought stakes while 176 increased positions. They now own 236.53 million shares or 0.67% less from 238.13 million shares in 2016Q1.
Federated Pa has 0.03% invested in the company for 129,885 shares. Sivik Global Healthcare Ltd Company has 2.78% invested in the company for 65,000 shares. Bb&T last reported 0.02% of its portfolio in the stock. Axa owns 630,175 shares or 0.24% of their US portfolio. Cornerstone Advsr accumulated 0.04% or 460 shares. Ubs Asset Americas Inc accumulated 2.78 million shares or 0.27% of the stock. Piedmont Invest Advsrs Lc has invested 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Rhumbline Advisers holds 0.1% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 377,088 shares. Partner Fund Mgmt L P holds 0.35% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 135,487 shares. Tokio Marine Asset Mngmt Ltd owns 7,880 shares or 0.07% of their US portfolio. Mackenzie Finance has 122,107 shares for 0.06% of their US portfolio. Moreover, Glg Ltd Partnership has 0.01% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 5,029 shares. Blue Jay Cap Mgmt last reported 125,450 shares in the company. The Connecticut-based Ardsley Advisory has invested 0.04% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Plante Moran Financial Ltd Com last reported 175 shares in the company.
Insider Transactions: Since April 13, 2016, the stock had 0 insider buys, and 28 insider sales for $16.45 million net activity. Shares for $16,576 were sold by SMITH IAN F. $443,739 worth of shares were sold by BOGER JOSHUA S on Wednesday, May 11. Silva Paul M also sold $16,576 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. $104,444 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Arbuckle Stuart A. 117 shares were sold by Sachdev Amit, worth $9,555.
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has a market cap of $19.27 billion. The Firm operates in pharmaceuticals segment. It currently has negative earnings. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications.
VRTX Company Profile
Vertex Pharmaceuticals Incorporated (Vertex), incorporated on January 4, 1989, is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Firm operates in pharmaceuticals segment. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Vertex’s two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. The Company’s VX-661 is a corrector compound that the Company is evaluating a Phase III development program in combination with ivacaftor in multiple CF patient populations having approximately one copy of the F508del mutation in their CFTR gene. The Company’s VX-371 is an investigational epithelial sodium channel (ENaC) inhibitor that is being evaluated in a Phase II development program. The Company’s VX-152 and VX-440 are two next-generation CFTR corrector compounds that entered Phase I clinical trials.
Another recent and important Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news was published by Streetinsider.com which published an article titled: “Vertex Pharma (VRTX) Announces FDA Approval for ORKAMBI in Children 6-11 …” on September 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.